Benefits of the Network - What's in it for you

Researchers

As a clinician you are best suited to judge what your patient needs.  This is your opportunity to ensure that you play a role in guiding how patients should be assessed and treated, which drugs should be prioritised for clinical trials and what areas should be identified for further research.

As a subject matter expert you are in a good position to identify research priorities, train fellows towards translational research, submit projects and draft guidance for industry and trial regulators as well as acting as a PIPs expert.

Collaborating partners will be able to give feedback on which drugs need trial prioritisation across all classes. There will be a forum from which to influence standards of treatment and diagnosis, where partners will be able to raise concerns about ethical issues such as burden and consent.  Those participating in collaboration will be able to respond feasibility and design issues of timing, workload, access to patients, methodology, endpoints, relevance to name but a few.  The collaborative network will form a platform for conducting PIPs.

Industry

As an industry partner you will have access to a wide range of trial patient recruitment and improved quality of results.  You will be able to see which drugs are receiving positive results and where the need is for drug trial prioritisation.  You will be able to optimise PIPs and study protocols.  This is an opportunity to provide the best treatment outcomes for young and vulnerable patients, to be involved in the improvement of patient care and standard setting across Europe and the rest of the modern world.